First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combi

[News]

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

More... (http://www.news-medical.net/news/20150818/First-patient-enrolled-in-Phase-II-trial-of-ImmunoPulse-IL-12-and-pembrolizumab-combination-therapy.aspx)